Healthcare Industry News: Dermal Filler
News Release - March 7, 2008
Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)LAUSANNE, Switzerland, March 7 (HSMN NewsFeed) -- Galderma Pharma, S.A. announces an agreement with ZARS Pharma, Inc. giving Galderma exclusive rights for all markets outside the USA and Canada for promotion and distribution of a novel topical anesthetic cream. This partnership follows an agreement signed last year between Galderma and ZARS Pharma for the promotion and distribution of Pliaglis(TM) in the USA and Canada.
"This agreement gives us a new opportunity to contribute to progress in patient care worldwide," said Humberto C. Antunes, CEO of Galderma. "As the market for corrective and aesthetic procedures continues to grow, Pliaglis(TM), with its unique vehicle and comfort of use for both patient and doctor is poised to fill an important unmet need. This agreement is part of our strategy to offer a comprehensive range of products that improve corrective and aesthetic procedural outcomes and complement our current family of therapeutic Rx and OTC products throughout the world."
Pliaglis(TM) (lidocaine and tetracaine) Cream 7%/7% is the first FDA-approved prescription-strength lidocaine and tetracaine combination topical anesthetic cream indicated to provide topical local analgesia for superficial dermatological procedures such as, among others, Dermal Filler injections, facial laser resurfacing and laser-assisted tattoo removal.
Formulated in a unique cream vehicle, Pliaglis(TM) is easily applied to the skin and forms a pliable self-occlusive mask which is easily peeled off the skin prior to a procedure. Pliaglis(TM) is a versatile new tool for use in many of the most common corrective and aesthetic procedures. With proven clinical efficacy, a unique phase-changing vehicle and an onset of action between 20-30 minutes, Pliaglis(TM) represents a technological innovation in patient's comfort.
"We are convinced that Pliaglis(TM) will be very well received by dermatologists and other physicians in Europe and Asia," said Francois Fournier, Vice-President EURMEAAS (Europe, Middle-East, Africa, Australia and Asia).
The corrective and aesthetic procedures market has more than doubled in the last five years with doctors using topical anesthetics for one in four of those procedures.
Galderma launched Pliaglis(TM) earlier this year in the USA and expects to file it with the regulatory authorities in the main worldwide markets later in 2008.
This license follows several recent transactions aimed at enriching Galderma's product offering to dermatology patients.
Galderma, created in 1981 as a joint venture between Nestle and L'Oreal, is a fully integrated specialty pharmaceutical company dedicated exclusively to dermatology. The Company has a presence in 65 countries with over 1000 sales representatives and is committed to improving the health of skin with an extensive line of products that treat a range of dermatological conditions including: acne, rosacea, fungal nail infections, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancers and medical solutions for skin senescence.
Galderma's new centre in Sophia Antipolis, France is the largest facility in the world dedicated to Research and Development in dermatology.
Galderma leading brands include Differin®, Rozex®/Metro®, Clobex®, Tri-Luma®, Loceryl® and Cetaphil®. Recently launched products include Pliaglis(TM), a topical anaesthetic for dermatologic procedures in the United States, Epiduo®, an innovative combination product for the treatment of acne in Europe and Argentina and Dysport®, an injectable neuro-modulator for the correction of wrinkles in Brazil and Argentina. The Company's website is http://www.galderma.com.
About ZARS Pharma:
ZARS Pharma is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs using proprietary drug delivery technologies, primarily in the area of pain management and dermatology. ZARS Pharma has developed a rich portfolio of proprietary products and product candidates based on the CHADD technology and on cream technologies (Peel and DuraPeel(TM)) that transform, or phase-change, from an initial liquid phase to a solid phase during application. ZARS Pharma's product portfolio includes two products that have been approved for marketing (Pliaglis(TM) and Synera, the latter marketed as Rapydan in Europe). ZARS Pharma currently has one product in a late-stage clinical trial that commenced in June 2007 (ThermoProfen(TM)) and four additional products that have entered various stages of clinical development. For more information on ZARS Pharma, please visit http://www.zars.com.
Differin®, Metrogel®, Clobex®, Tri-Luma®, Cetaphil® and Epiduo® are trademarks of Galderma Pharma S.A.
Pliaglis(TM) is a trademark of ZARS Pharma, Inc. and Dysport® is a trademark of Ipsen Ltd.
Source: Galderma Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.